Literature DB >> 1883380

Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium.

H S Cross1, C Huber, M Peterlik.   

Abstract

Depending on culture in either "low Ca++" (0.25 mM) or "normal Ca++" (1.8 mM) medium, human colon adenocarcinoma-derived CaCo-2 cells exhibit differential sensitivity to the antiproliferative action of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and of two side-chain modified analogs, 1,25S,26-trihydroxy-delta 22-vitamin D3 (Ro 23-4319) and 1,25-dihydroxy-delta 16-23yne-vitamin D3 (Ro 23-7553). CaCo-2 cells cultured under low Ca++ conditions exhibit a high proliferative potential, and in these cells, all vitamin D compounds under investigation significantly inhibit [3H]thymidine incorporation into cellular DNA at greater than or equal to 10(-10) M. The rank order of biopotency is: Ro 23-7553 greater than or equal to Ro 23-4319 greater than 1,25(OH)2D3. At 1.8 mM Ca++, only Ro 23-7553 is able to inhibit proliferation of CaCo-2 cells. Parallel to their antiproliferative action, all three vitamin D compounds stimulate akaline phosphatase activity in CaCo-2 cells, indicating their ability to induce differentiated functions at the same time as they reduce neoplastic cell growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1883380     DOI: 10.1016/0006-291x(91)91333-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.

Authors:  Kathryn M Wilson; Irene M Shui; Lorelei A Mucci; Edward Giovannucci
Journal:  Am J Clin Nutr       Date:  2014-11-19       Impact factor: 7.045

2.  Role of bile acid secretion in human colorectal cancer.

Authors:  Meinrad Peterlik
Journal:  Wien Med Wochenschr       Date:  2008

3.  Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25 [OH]2 D3) on head and neck squamous cell carcinoma cell lines.

Authors:  J Kornfehl; M Formanek; A Temmel; B Knerer; M Willheim
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

4.  Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: relation to in vitro hypercalcemic potential.

Authors:  H S Cross; K H Farsoudi; M Peterlik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

5.  Inhibition of development of N,N'-dimethylhydrazine-induced rat colonic aberrant crypt foci by pre, post and simultaneous treatments with 24R,25-dihydroxyvitamin D3.

Authors:  E I Salim; H Wanibuchi; T Taniyama; Y Yano; K Morimura; S Yamamoto; S Otani; Y Nishizawa; H Morii; S Fukushima
Journal:  Jpn J Cancer Res       Date:  1997-11

6.  Association between blood circulating vitamin D and colorectal cancer risk in Asian countries: a systematic review and dose-response meta-analysis.

Authors:  Lin Zhang; Huachun Zou; Yang Zhao; Chunlei Hu; Adejare Atanda; Xuzhen Qin; Peng Jia; Yu Jiang; Zhihong Qi
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

Review 7.  Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System.

Authors:  Sicheng Zhang; Duane D Miller; Wei Li
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

Review 8.  The Use of 1α,25-Dihydroxyvitamin D₃ as an Anticancer Agent.

Authors:  Ewa Marcinkowska; Graham R Wallace; Geoffrey Brown
Journal:  Int J Mol Sci       Date:  2016-05-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.